GlassScriptPhysician profile
Ranbir S Dhillon
NPI 1124090691
$182,241.48
in general payments reported to CMS, 2019-2025
69 companies · $6,456 in 2025
The $6,456 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $27K · 2021: $23K · 2022: $28K · 2023: $17K · 2024: $16K · 2025: $6,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,156 · Travel and Lodging: $3,059 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,852.47 |
| Consulting Fee | $11,610.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,156.00 |
| Travel and Lodging | $3,059.00 |
| Education | $293.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $51,620.24 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Genzyme Corporation | $37,004.15 | 2019-2025 | |
| Celgene Corporation | $27,078.36 | 2019-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $21,345.60 | 2020-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $8,622.54 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $4,639.54 | 2019-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $3,932.09 | 2019-2025 | |
| Lundbeck LLC | $2,591.99 | 2020-2025 | Vyepti, Rexulti |
| Abbvie INC. | $2,167.27 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Sk Life Science, INC. | $2,038.87 | 2020-2025 | |
| Livanova USA, INC. | $1,706.05 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Merz Pharmaceuticals, LLC | $1,218.92 | 2021-2025 | Xeomin, Inbrija |
| Janssen Pharmaceuticals, INC | $1,142.13 | 2020-2023 | Ponvory |
| Neurocrine Biosciences, INC. | $1,065.42 | 2019-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $1,018.29 | 2019-2025 | Ongentys, Rytary, Crexont |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $998.62 | 2020-2025 | Ultomiris |
| Ucb, INC. | $996.19 | 2019-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Pfizer INC. | $985.82 | 2021-2025 | |
| Genentech USA, INC. | $950.28 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Neurelis, INC. | $904.00 | 2020-2025 | Valtoco |
| Lilly USA, LLC | $868.92 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Biohaven Pharmaceuticals, INC. | $767.51 | 2021 | |
| Amgen INC. | $675.45 | 2019-2025 | Uplizna, Aimovig |
| Eisai INC. | $584.01 | 2019-2025 | |
| Csl Behring | $569.12 | 2020-2025 | Hizentra |
| Mallinckrodt Hospital Products INC. | $562.44 | 2020-2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $519.36 | 2022 | |
| Sunovion Pharmaceuticals INC. | $508.42 | 2019-2022 | |
| Mdd US Operations, LLC | $489.63 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Kyowa Kirin, INC. | $413.62 | 2020-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $403.90 | 2020-2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $345.26 | 2021-2025 | Ponvory |
| Grifols USA, LLC | $307.03 | 2019-2025 | Gamunex-C |
| Allergan, INC. | $236.87 | 2019-2022 | |
| Acorda Therapeutics, INC | $230.76 | 2019-2023 | Inbrija |
| Sumitomo Pharma America, INC. | $217.90 | 2023-2024 | Aptiom |
| Mallinckrodt Enterprises LLC | $213.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $209.53 | 2019 | |
| Argenx US, INC. | $167.18 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $162.34 | 2023-2024 | Dysport |
| Otsuka America Pharmaceutical, INC. | $123.97 | 2023-2025 | Rexulti, Nuedexta |
| Merz North America, INC. | $121.34 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $112.63 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $110.68 | 2023-2025 | Purified Cortrophin Gel |
| Upsher-Smith Laboratories LLC | $100.92 | 2019-2022 | |
| Banner Life Sciences, LLC | $100.87 | 2021-2022 | |
| Inspire Medical Systems, INC. | $89.56 | 2024-2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $86.53 | 2021-2023 | Keveyis |
| Sanofi-Aventis U.S. LLC | $82.88 | 2020 | |
| Neuropace, INC. | $77.70 | 2022-2025 | |
| Impel Pharmaceuticals INC. | $72.31 | 2023 | Trudhesa |
| Ge Healthcare | $71.23 | 2019-2023 | |
| Tanabe Pharma America, INC. | $57.43 | 2019-2024 | |
| Catalyst Pharmaceuticals, INC. | $54.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $49.89 | 2025 | Wainua |
| Medtronic, INC. | $48.02 | 2022-2023 | Merocel |
| Horizon Therapeutics Plc | $47.33 | 2021-2022 | |
| Microtransponder, INC. | $45.42 | 2025 | |
| Bardy Diagnostics, INC. | $45.00 | 2021 | |
| Life Molecular Imaging LTD | $41.08 | 2023-2025 | Neuraceq |
| Avion Pharmaceuticals | $36.61 | 2022-2023 | Dhivy |
| Tg Therapeutics, INC. | $35.25 | 2024 | |
| Jazz Pharmaceuticals INC. | $32.95 | 2020-2024 | |
| Avanir Pharmaceuticals, INC. | $31.67 | 2019 | |
| Genentech, INC. | $23.76 | 2023 | Ocrevus, Enspryng |
| Vertical Pharmaceuticals, LLC | $20.43 | 2019 | |
| Medtronic USA, INC. | $16.98 | 2019 | |
| Watermark Medical, INC. | $13.47 | 2024 | |
| Strongbridge US INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranbir Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.